PipelineReview.com | Business Intelligence Center - Allon begins dosing for AL-108 Phase Ib clinical trial

PipelineReview.com | Business Intelligence Center - Allon begins dosing for AL-108 Phase Ib clinical trial: "Allon Therapeutics Inc. announced it has begun dosing in a Phase Ib human clinical trial evaluating the Company’s product AL-108 as a treatment for Alzheimer’s disease. "